title: Preattack vaccination against anthrax may be cost-effective in certain populations.
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Hopkins
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Waytes
authors.forename: Thomas K
authors.initials: TK
authors.lastname: Zink
mesh_terms: D000881:Anthrax / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000191:economics* / Q000627:therapeutic use; D023482:Bioterrorism; D018890:Chemoprevention; D003362:Cost-Benefit Analysis; D006801:Humans
chemical_list: D022122:Anthrax Vaccines